14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TAK vs VIR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TAK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)
TAK Overall Winner
6-Pillar Tally: TAK 4 – 2 VIR
Matrix Metrics: TAK 7 – 3 VIR
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Vir Biotechnology, Inc. (VIR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas VIR carries 41.0/100 (SELL) at $9.76 (4.3x Forward P/E, -70.2% operating margin).
Growth vs. Quality Trade-Off: TAK earns the overall head-to-head edge with a stronger Unified Composite Score (47.7/100 HOLD vs. VIR 41.0/100 SELL) and -0.02β · 22% Vol risk profile, whereas VIR leads top-line expansion (+19582.5% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 73.1); meanwhile VIR is in a Breakdown options structure phase (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs VIR. Trailing 12-month operating profitability (TAK 16.6% vs VIR -70.2%) and valuation multiples (TAK 12.7x vs VIR 4.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment48.2% of Rev ($12.4B)
90D Engineering Disclosures0 Published
VIR Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -70.2% operating margin.
OpEx & R&D Reinvestment33.5% of Rev ($101M)
90D Engineering Disclosures0 Published
Investor FAQ TAK vs VIR Key Questions & Quantitative Answers
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Vir Biotechnology, Inc. (VIR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas VIR carries 41.0/100 (SELL) at $9.76 (4.3x Forward P/E, -70.2% operating margin). Growth vs. Quality Trade-Off: TAK earns the overall head-to-head edge with a stronger Unified Composite Score (47.7/100 HOLD vs. VIR 41.0/100 SELL) and -0.02β · 22% Vol risk profile, whereas VIR leads top-line expansion (+19582.5% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 73.1); meanwhile VIR is in a Breakdown options structure phase (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VIR leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with VIR at +19582.5% YoY revenue growth and +58.5% YoY earnings growth on $303M TTM revenue (-36.7% gross margin, -70.2% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $303M for VIR. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 33.5% of Rev ($101M) (0 disclosures) for VIR.
VIR screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas VIR trades at 4.3x Forward P/E, 4.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-46.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus VIR (-21.8% ROE) capital efficiency.
In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, VIR carries 69.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.20x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.71β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.